1 Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in

2 eastern Ethiopia

- 3 Nega Assefa^{1,2, *}, Lemma Demissie¹, Zelalem Teklemariam¹, Joseph Oundo², Lola Madrid²,
- 4 Addisu Kebede³, Yadeta Dessie¹, J. Anthony G. Scott²
- ¹College of Health and Medical Sciences, Haramaya University, Ethiopia
- ² London School of Hygiene & Tropical Medicine, UK
- 9 ³ Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- 10
- 11 * corresponding author
- 12 Nega Assefa
- 13 Email: <u>negaassefa@yahoo.com</u>
- 14
- 15 Contact address
- 16 NA: <u>negaassefa@yahoo.com</u>
- 17 LDR: <u>esraeldemiss@gmail.com</u>
- 18 ZT: zelalemtmariam@yahoo.com
- 19 LM: lola.madrid-castillo@lshtm.ac.uk
- 20 JO: joseph.oundo@lshtm.ac.uk
- 21 YD: yad_de2005@yahoo.com
- 22 JAGS: anthony.scott@lshtm.ac.uk
- 23
- 24 Target Journal
- 25
- 26 Word counts
- 27Abstract245
- 28 Main text 2231
- 29
- 30

31 Abstract

Information on the cumulative incidence of SARS-CoV-2 in East Africa is scarce. We conducted
 serosurveillance of anti–SARS-CoV-2 antibodies among pregnant women attending their first
 antenatal care visit in three health facilities in eastern Ethiopia.

We collected data using questionnaire and a blood sample from 3,312 pregnant women between April 1, 2020 and March 31, 2021 at health facilities in Haramaya, Aweday and Harar. We selected 1,447 blood samples at random and assayed these for anti-SARS-CoV-2 antibodies at Hararghe Health Research laboratory using WANTAI® SARS-CoV-2 Rapid Test for total immunoglobulin. Temporal trends in seroprevalence were analysed with a χ^2 test for trend and multivariable binomial regression.

Among 1,447 sera tested, 83 were positive for anti–SARS-CoV-2 antibodies giving a crude seroprevalence of 5.7% (95% CI 4.6%, 7.0%). Of 160 samples tested in April-May, 2020, none was seropositive; the first seropositive sample was identified in June and seroprevalence rose steadily thereafter (χ^2 test for trend, p=0.003) reaching a peak of 11.8% in February, 2021. In the multivariable model, seroprevalence was approximately 3% higher in first-trimester mothers compared to later presentations, and rose by 0.75% (95% CI 0.31%, 1.20%) per month of calendar time.

48 This clinical convenience sample illustrates the dynamic of the SARS-CoV-2 epidemic in young 49 adults in eastern Ethiopia; infection was rare before June 2020 but it spread in a linear fashion 50 thereafter, rather than following intermittent waves, and reached 10% by the beginning of 2021. 51 After one year of surveillance, most pregnant mothers remained susceptible.

52 Keywords: COVID 19, COVID-19 seroprevalence, COVID-19 among pregnant women,

53 COVID-19 in Ethiopia

54

55 Introduction

56 In Ethiopia, the first case of COVID-19 was reported on 13 March 2020. By the end of March 57 2021 there were 206,589 reports of COVID-19 infection and 2,865 coronavirus-related deaths. In 58 a country with an estimated population, in 2019, of 112 million this represents a cumulative 59 incidence of SARS-CoV-2 infection of only 0.2% after a full year of transmission. Many cases 60 of COVID-19 present with mild symptoms and, in Ethiopia, three quarters of PCR-positive cases 61 have no symptoms [1,2]. Access to PCR testing in Ethiopia is also sparse. Monitoring the 62 epidemic by detecting symptomatic cases is, therefore, highly insensitive. In these 63 circumstances, seroprevalence of anti-SARS-CoV-2 antibodies can provide a more accurate 64 estimator of cumulative incidence. Undertaking community serosampling during the pandemic is 65 difficult when travel and household access are constrained by control measures. Expectant 66 mothers, however, are likely to continue to seek health services throughout the pandemic and 67 they can be used as a continuously-available proxy population to estimate the cumulative 68 incidence among young adults [3-5]. In addition, serological surveillance is simple to implement 69 at ANC clinic visits because anti-SARS-CoV-2 antibodies can be assayed in the residual blood 70 volumes of routine samples collected for clinical screening for anemia and maternal infectious 71 diseases.

Planning and provision of health care during a major epidemic like COVID-19 pose substantial logistical and clinical challenges. Information on the shape of the epidemic curve is critical to inform public health responses. The dynamics of seroprevalence reflect the epidemic curve and can provide an estimate of the effective reproduction number. Seroprevalence also indicates the likelihood of approaching transmission control through population immunity. This study aimed

to assess the trend in seroprevalence of anti-SARS-CoV-2 antibodies throughout the first year of

- the epidemic by assaying anti-SARS-CoV-2 antibodies among pregnant women attending ante-
- natal clinic at three different health facilities in the area around Harar, eastern Ethiopia.

80 **Results**

81 Demographic characteristics of the study participants

- 82 Between April 1, 2020 and March 31, 2021 there were 3,313 first visits to the antenatal clinics;
- 83 1,532 (46.24%) at Hiwot Fana Hospital, 1781 (53.75%) at Aweday Health Centre and Haramaya
- 84 Hospital. At these, we interviewed and collected blood samples from 3,312 women. We tested a
- random sample of 1,447 blood specimens (Table 1); 752 (52%) were from Haramaya District
- 86 (Aweday Health Centre and Haramaya Hospital) and 695 (48%) were from Hiwot Fana Hospital;
- 87 984 (68%) were urban residents (Table 1).

88 Table 1. Characteristics of 1,447 pregnant mothers attending their first antenatal care at the two

89	study area	as between	April	2020 and	March	2021 a	and sam	pled a	at random	for	the	study	y
----	------------	------------	-------	----------	-------	--------	---------	--------	-----------	-----	-----	-------	---

Characteristics	Hara Dist	Haramaya District		Fana pital	Total		
	n	%	n	%	n	%	
Age in years							
14-19	98	13.0	74	13.5	192	13.3	
20-24	341	45.4	268	35.6	588	40.7	
25-29	181	24.1	219	31.6	400	27.7	
30-34	110	14.6	100	14.4	210	14.5	
>=35	22	2.9	35	4.9	56	3.9	
Residence							
Urban	577	76.8	407	58.7	984	68.1	
Rural	174	23.2	287	41.4	461	31.9	

Number of children						
None	298	40.0	254	36.8	552	38.4
1-5	422	56.6	401	58.1	823	57.3
6-10	26	3.5	35	5.1	61	4.3
Trimester of visit						
First	223	29.7	143	20.6	366	25.3
Second	416	55.3	242	34.8	658	45.5
Third	113	15.0	310	44.6	423	29.2
Comorbidities						
None	750	99.7	689	99.1	1,439	99.5
At least one*	2	0.3	6	0.9	8	0.6
COVID symptoms†						
No	721	96.4	668	96.5	1,389	96.5
Yes	27	3.6	24	3.5	51	3.5

90

91 * chronic liver, renal, cardiovascular or 'other' disease

92 [†] at least one of cough, fever, headache or difficulty breathing

93

Among the population sample tested, the mean (SD) age was 23.9 (4.7) years and ages ranged from 15 to 45 years. The mean (SD) number of children per mother was 1.5 (1.8). The median (IQR) gestational age at the first antenatal visit was 20 (13-28) weeks. Only 51 (3.5%) had COVID-19 symptoms at the time of sampling and 8 (<1%) had a history of comorbidity, given as chronic liver, renal, cardiovascular or 'other' disease. Respiratory diseases, chronic neurological disease, diabetes mellitus, and cancer were not reported by any participant (Table 2).

101 Table 2. Seroprevalence of Anti-SARS-CoV-2 antibodies by participant characteristics.

		Sero-	Sero-	
Characteristics	Tested	positive	prevalence	χ^2 test

	Ν	n	%	
Age in years				
14-19	192	7	3.7	p=0.19
20-24	588	42	7.1	
25-29	400	24	6.0	
30-34	210	9	4.3	
>=35	56	1	1.8	
ANC clinic				
Hiwot Fana Hospital	695	35	5.0	p=0.26
Haramaya Hospital	19	0	0.0	
Aweday Health Centre	733	48	6.6	
Residence				
Urban	984	57	5.8	p=0.91
Rural	461	26	5.6	
Number of children				
None	520	32	5.8	P=0.370
1-5	778	45	5.5	
6-10	55	6	9.8	
Trimester of visit				
First	366	31	8.5	p=0.034
Second	658	32	4.9	
Third	423	20	4.8	
Comorbidities				
None	1,439	81	5.6	p=0.019
At least one*	8	2	25.0	
COVID symptoms†				
No	1,389	82	5.9	p=0.24
Yes	51	1	2.0	

102

103 * chronic liver, renal, cardiovascular or 'other' disease

104 [†] at least one of cough, fever, headache or difficulty breathing

105 Seroprevalence of SARS-CoV-2 antibodies

106 Of 1,447 samples tested, 83 (5.7%, 95% CI 4.6, 7.0%) were positive for anti-SARS-CoV-2

107 antibodies. The first seropositive sample was identified on June 11, 2020, and seroprevalence

108 rose progressively thereafter, with the exception of March 2021, where it dropped sharply (χ^2 for





Figure 1: Temporal trend of seroprevalence of anti–SARS-CoV-2 antibodies among pregnant
women presenting for first antenatal care in 3 ANC facilities, eastern Ethiopia, between
April 1, 2020 and March 31, 2021

Seroprevalence also varied significantly by trimester of pregnancy and co-morbidity but not by clinic, residence or COVID-19 symptoms (Table 2). Given the linear growth in seroprevalence (Figure 1) and better model fit based on Bayesian information criterion, we modelled prevalence

associations as risk differences rather than risk ratios. In a multivariable binomial regression
model, the prevalence difference was -3.2% (95% CI -6.7, -0.4%) and -3.0% (95% CI -6.8, 0.8%) among women in their second and third trimesters, respectively, compared with those in
the first trimester and the prevalence difference was 0.75% (95% CI 0.31, 1.20%) per month of
calendar time.

122 **Discussion**

123 The study provides a simple description of the dynamic of SARS-CoV-2 epidemic in an area 124 where reliable data are extremely rare. In a population of attendees at ante-natal clinics in three 125 sites in eastern Ethiopia, antibodies against SARS-CoV-2 first appeared in June 2020 and 126 seroprevalence rose steadily month on month reaching approximately 10% at the beginning of 127 2021. Although the point estimate for March 2021 is substantially lower, the data as a whole 128 evince a strong linear trend and this single estimate is most likely to have deviated from the 129 general direction by chance. If these results are reliable, they indicate that the epidemic is 130 progressing here at a considerably lower rate than in other settings in East Africa and that the 131 greater majority of the population remains uninfected, suggesting that the epidemic is still at an 132 early stage.

The principal limitations of the study are the potential generalisability of the population under surveillance and the validity of the serological assay employed. Pregnant women have been used as an indicator population in prior pandemics, including HIV [6], but also for SARS-CoV-2, both in high-income settings [4,5,7-11] and low- and middle-income settings, including in neighbouring Kenya [3]. The principal advantage of sampling pregnant women is that they

138 remain one of the few patient groups for whom health services cannot be postponed until after 139 the pandemic has passed. They are permitted and encouraged to attend even in the face of social 140 and movement restrictions, and so provide a consistent and reliable sampling group. The 141 principal limitation of this group is their restriction on age and sex, however, in most settings, 142 including other East African countries, seroprevalence does not vary significantly by sex and the 143 cumulative incidence in women is likely to represent the infection history of both sexes [12]. 144 Similarly, in most settings young adults are the group most likely to be infected by SARS-CoV-2 145 and so the seroprevalence estimates here are likely to represent the highest risk in the whole 146 population; other age groups, particularly children and the elderly, are likely to have lower 147 seroprevalence [13,14].

148 The World Health Organization has deprecated the use of rapid tests for SARS-CoV-2 antibodies 149 for individual diagnosis but recognises their potential value in research [15]. WHO has also recommended and endorsed quantitative analysis of IgG antibodies using ELISA and has 150 151 distributed the WANTAI ELISA kit to countries undertaking serosurveillance. Reliance on 152 ELISA, however, limits the range of settings in which serosurveillance can be undertaken and 153 lateral flow tests have been successfully employed for recurrent community-based nationwide 154 surveys in the UK [16]. When seroprevalence is low, as at the beginning of our study, an assay 155 with imperfect specificity may detect more false positives than true positives. The specificity of 156 the WANTAI rapid test has been estimated by the manufacturer at 98.8%. We assayed 80 157 samples each month in April and May 2020 without observing a single positive test, suggesting 158 that the specificity is indeed very high. Even if the positive results identified in June included 159 false positives, the progressive rise in seropositivity with time is most unlikely to be influenced 160 materially by a small fraction of false positive results.

The assay sensitivity may also be imperfect in detecting prior infection because the assay was 161 162 originally calibrated against sera from symptomatic cases, who generally have higher antibody 163 levels than asymptomatic individuals [17], and because pregnant women who were infected 164 several months ago may have experienced waning of antibody levels and seroreversion [18-22]. 165 In general, seroreversion is less problematic in assays that measure total immunoglobulin and in 166 those that target spike antigens, compared to nucleocapsid antigens [20,23], so problem of 167 waning in this study is unlikely to be substantial. Furthermore, if sensitivity is unlikely to decline 168 over time, imperfect sensitivity would not affect the shape of the rising seroprevalence line, 169 though it would underestimate the gradient. If, as estimated in one validation study, the 170 WANTAI rapid test has a sensitivity of only 89% [24], adjustment for test-performance 171 characteristics would elevate our reported seroprevalence results by a factor of 1.12.

The results are in contrast to most other settings studied which record a sharp take-off in seroprevalence once transmission begins, often rising quickly to high levels. In Kenya for example, women attending an ANC clinic in Kilifi had seroprevalence of 0%, 2% and 11% in consecutive months September-November 2021; those attending ANC clinic in Nairobi had a seroprevalence of 50% in August 2020 [3]. The pattern illustrated in eastern Ethiopia is more indicative of a gradually spreading epidemic curve suggesting an effective reproduction number much closer to 1.

In Juba, South Sudan, seroprevalence was 22% in a household survey in August-September 2020
[25]; in Kenya, a national estimate for seroprevalence, based on testing blood transfusion donors,
was 4.3% in May 2020 [12] and 9.1% two months later [26]. Health Care Workers in Nairobi,
Kenya, had a seroprevalence of 44% in August 2020; those in two rural hospitals had

183 seroprevalence of 12-13% in November 2020 [27]. Finally, in Addis Ababa seroprevalence, 184 estimated in May 2020, was 3.0% [28]. Although all these studies used different laboratory 185 assays and varied statistical adjustments, collectively, they suggest that transmission in eastern 186 Ethiopia began later than in much of the rest of the region, including the state capital, and has 187 progressed more slowly.

In summary if seroprevalence is a reliable indicator of cumulative incidence, SARS-CoV-2 infection is spreading slowly but steadily in eastern Ethiopia. This contrasts sharply with the recurrent waves of PCR-positive infections apparent in the national surveillance system. One year after the start of the epidemic approximately 10% of women attending ante-natal clinics are seropositive implying that the COVID-19 epidemic is still at an early stage in eastern Ethiopia.

193 Material and methods

194 **Study area and period**

195 The surveillance was conducted between April 1, 2020 and March 31, 2021 at Aweday Health Centre and Haramaya District Hospital, both in Haramaya District, and in Hiwot Fana 196 197 Specialized Referral University Hospital in Harar. Hiwot Fana is the largest referral and teaching 198 hospital in eastern Ethiopia and receives tertiary referrals from Harari region, East Oromia, 199 Somali region, and Dire Dawa City. It is one of the ten regional centres designated by the 200 Federal Ministry of Health to manage the COVID-19 epidemic. Haramaya Hospital was rapidly 201 designated a COVID-19 treatment facility and women seeking ANC services were therefore 202 referred to Aweday Health Centre after April 16, 2020.

203 Study design, population and sample size

204 At the end of March 2020, we integrated Health facility-based surveillance into the routine 205 clinical care of pregnant women at Hiwot Fana Hospital, Aweday Health Centre and Haramaya 206 Hospital. The study population comprised 3306 pregnant women attending their first antenatal 207 care in these three facilities during the surveillance period. A total 78 women were excluded 208 because they were not willing to provide blood sample. Routine antenatal care includes 209 serological screening for HIV, syphilis, and toxoplasma infection during pregnancy undertaken 210 in two blood samples; the first blood sample is taken at 16 weeks' gestation or at the first ANC 211 visit, if later.

Socio-demographic data and information on pregnancy, clinical symptoms of COVID-19 and comorbidities was collected by trained nurses. COVID-19 symptoms were defined as at least one
of cough, fever, headache or difficulty breathing. Data quality and completeness were checked
daily.

216 Laboratory analyses

For the anti–SARS-CoV-2 antibodies test, residual blood samples from the routine ANC tests were transferred to a test-tube containing clot activator by trained medical laboratory technologists working in each health facility. The blood samples were allowed to clot and serum was separated by centrifugation at 3000 RPM for 10 minutes. Serum samples were stored at 2-8°C at each site and transported in cool boxes to Hararghe Health Research Laboratory where they were stored at -80°C.

223 Samples were tested using WANTAI® SARS-CoV-2 Ab Rapid Test. The test is a lateral flow 224 assay in a cassette format designed for the qualitative detection of total antibodies to SARS-225 CoV-2 in human serum. The receptor-binding domain of the SARS-CoV-2 spike protein is 226 bound at the Test Zone (T) and antibodies are bound at the Control Zone (C) of the cassette. The 227 test has a sensitivity of 100% and specificity of 98.8% under validation performed by the manufacturer; independent validation of the test found a sensitivity of 89% [24]. All the stored 228 229 serum samples, tests reagents and cassettes were brought to room temperature (15-30°C) thiry 230 minutes before performing the test; 10µl of serum specimen and two drops of diluent buffer were 231 added into the specimen window. Results were read and interpreted as reactive/positive (Red line 232 on C and T) or non-reactive/negative (Red line on C) after 15-20 minutes [24,29]. Serum 233 samples taken \geq 14 days after a positive PCR test from COVID-19 infected individuals were used 234 as quality control.

235 Statistical analysis

We used STATA version 16.0 for statistical analysis. We estimated unadjusted seroprevalence of SARS-CoV-2 IgG antibody with a 95% confidence interval (CI). We did not make adjustment for the test performance characteristics because the manufacturer's validation assay, found very high sensitivity and specificity. We examined the univariate association between individual characteristics and seropositivity using χ^2 and multivariable associations using binomial regression. The trend in seropositivity with time was tested with a χ^2 test for trend and in the multivariable model.

243 **Ethical consideration**

The study was confined to residual clinical blood sample testing and anonymized questionnaire data. It was conducted as part of a public health surveillance, with the approval of the director of each of the three health facilities and the data were made available to relevant bodies including the Regional Health Bureau (Harari and Oromia) and the Ethiopian Public Health Institute (EPHI). Ethical clearance was secured from Institutional Health Research Ethical Review Committee of the College of Health and Medical Sciences, Haramaya University, Ethiopia.

Data availability

- 251 Data is available in the following link and can be requested using the form in the link.
- 252 <u>https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/XIWCXN.</u>

253 Acknowledgements

Activities of the surveillance and Laboratory analysis was supported by Emory University as part of the CHAMPS network (<u>www.champshealth.org</u>). JAGS was funded by The Wellcome Trust through a Senior Research Fellowship (214320).

257 Author contribution

NA and JAGS lead overall Surveillance. NA, JAGS, ZT and LDR develop concept of the Surveillance, analyzed the data and wrote the manuscript. ZT provided microbiome data analysis, and interpretation. NA, JAGS, ZT, LDR, LM, JO and YD reviewed the manuscript and give critical feedback. All authors approved the submission of the manuscript to the journal.

262 **Competing of interest**

263 The authors declare no competing interests.

264

265

266 **References**

- Abdela, S. G. *et al.* Clinical Profile and Treatment of COVID-19 Patients: Experiences
 from an Ethiopian Treatment Center. *Am J Trop Med Hyg*, doi:10.4269/ajtmh.20-1356
 (2020).
- Abraha, H. E. *et al.* Clinical features and risk factors associated with morbidity and
 mortality among patients with COVID-19 in northern Ethiopia. *Int J Infect Dis* 105, 776783, doi:10.1016/j.ijid.2021.03.037 (2021).
- 273 3 Lucinde, R. *et al.* Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in two
 274 Kenyan referral hospital. *medRxiv* submitted (2021).
- Lumley, S. F. *et al.* SARS-CoV-2 antibody prevalence, titres and neutralising activity in an
 antenatal cohort, United Kingdom, 14 April to 15 June 2020. *Euro Surveill* 25,
 doi:10.2807/1560-7917.ES.2020.25.41.2001721 (2020).
- Villalaín, C. *et al.* Seroprevalence analysis of SARS-CoV-2 in pregnant women along the
 first pandemic outbreak and perinatal outcome. *PLOS ONE* 15, e0243029,
 doi:10.1371/journal.pone.0243029 (2020).
- Kigadye, R. M. *et al.* Sentinel surveillance for HIV-1 among pregnant women in a
 developing country: 3 years' experience and comparison with a population serosurvey. *AIDS* 7, 849-855, doi:10.1097/00002030-199306000-00014 (1993).
- Cosma, S. *et al.* The "scar" of a pandemic: Cumulative incidence of COVID-19 during the
 first trimester of pregnancy. *J Med Virol* 93, 537-540, doi:10.1002/jmv.26267 (2021).
- 286 8 Crovetto, F. *et al.* Seroprevalence and presentation of SARS-CoV-2 in pregnancy. *Lancet*287 **396**, 530-531, doi:10.1016/S0140-6736(20)31714-1 (2020).
- Flannery, D. D. *et al.* SARS-CoV-2 seroprevalence among parturient women in
 Philadelphia. *Sci Immunol* 5, doi:10.1126/sciimmunol.abd5709 (2020).
- Haizler-Cohen, L., Davidov, A., Blitz, M. J. & Fruhman, G. Severe acute respiratory
 syndrome coronavirus 2 antibodies in pregnant women admitted to labor and delivery
 units. *Am J Obstet Gynecol* 224, 112-114, doi:10.1016/j.ajog.2020.09.022 (2021).
- Mattern, J. *et al.* Post lockdown COVID-19 seroprevalence and circulation at the time of
 delivery, France. *PLoS One* 15, e0240782, doi:10.1371/journal.pone.0240782 (2020).
- 295 12 Uyoga, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood
 296 donors. *Science* 371, 79-82, doi:10.1126/science.abe1916 (2021).

- 297 13 Murhekar, M. V. et al. SARS-CoV-2 antibody seroprevalence in India, August-September,
- 2020: findings from the second nationwide household serosurvey. *Lancet Glob Health* 9,
 e257-e266, doi:10.1016/S2214-109X(20)30544-1 (2021).
- Pollan, M. *et al.* Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide,
 population-based seroepidemiological study. *Lancet* **396**, 535-544, doi:10.1016/S01406736(20)31483-5 (2020).
- 30315WorldHealthOrganization.https://www.who.int/news-304room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-305for-covid-19 (2020).
- Moshe, M. *et al.* SARS-CoV-2 lateral flow assays for possible use in national covid-19
 seroprevalence surveys (React 2): diagnostic accuracy study. *BMJ* 372, n423,
 doi:10.1136/bmj.n423 (2021).
- Takahashi, S., Greenhouse, B. & Rodriguez-Barraquer, I. Are Seroprevalence Estimates
 for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? *J Infect Dis* 222, 17721775, doi:10.1093/infdis/jiaa523 (2020).
- Ibarrondo, F. J. *et al.* Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild
 Covid-19. *N Engl J Med* 383, 1085-1087, doi:10.1056/NEJMc2025179 (2020).
- Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2
 infections. *Nat Med* 26, 1200-1204, doi:10.1038/s41591-020-0965-6 (2020).
- Lumley, S. F. *et al.* The duration, dynamics and determinants of SARS-CoV-2 antibody
 responses in individual healthcare workers. *Clin Infect Dis*, doi:10.1093/cid/ciab004
 (2021).
- Muecksch, F. *et al.* Longitudinal Serological Analysis and Neutralizing Antibody Levels in
 Coronavirus Disease 2019 Convalescent Patients. *J Infect Dis* 223, 389-398,
 doi:10.1093/infdis/jiaa659 (2021).
- Ward, H. *et al.* Prevalence of antibody positivity to SARS-CoV-2 following the first peak
 of infection in England: Serial cross-sectional studies of 365,000 adults. *Lancet Reg Health Eur* 4, 100098, doi:10.1016/j.lanepe.2021.100098 (2021).
- Post, N. *et al.* Antibody response to SARS-CoV-2 infection in humans: A systematic
 review. *PLoS One* 15, e0244126, doi:10.1371/journal.pone.0244126 (2020).

327	24	Weidner, L	. et al. Quantificat	tion of SAI	RS-Co	V-2 antibo	dies with ei	ight con	nmercially
328		available	immunoassays.	Journal	of	Clinical	Virology	129,	104540,
329		doi: <u>https://</u>	/doi.org/10.1016/j.j	<u>cv.2020.104</u>	1 <u>540</u> (2	2020).			

- Wiens, K. E. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Juba, South
 Sudan: a population-based study. *medRxiv*, doi:10.1101/2021.03.08.21253009 (2021).
- Adetifa, I. M. O. *et al.* Temporal trends of SARS-CoV-2 seroprevalence in transfusion
 blood donors during the first wave of the COVID-19 epidemic in Kenya. *medRxiv*,
 doi:https://www.medrxiv.org/content/10.1101/2021.02.09.21251404v1 (2021).
- Etyang, A. O. *et al.* Seroprevalence of Antibodies to SARS-CoV-2 among Health Care
 Workers in Kenya. *Clin Infect Dis*, doi:10.1093/cid/ciab346 (2021).
- 337 28 Kempen, J. H. *et al.* SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia. *Am J Trop Med* 338 *Hyg* 103, 2022-2023, doi:10.4269/ajtmh.20-0816 (2020).
- 339 29 The WANTAI SARS-CoV-2 Ab Rapid Test. Beijing Wantai Biological Pharmacy
 340 Enterprise Co., Ltd. No.31 <<u>www.ystwt.com</u> > (2020).

341

342